Mn Services Vermogensbeheer B.V. Lowers Holdings in Eli Lilly and Company (NYSE:LLY)

Mn Services Vermogensbeheer B.V. decreased its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 2.5% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 344,688 shares of the company's stock after selling 8,700 shares during the period. Eli Lilly and Company accounts for 1.8% of Mn Services Vermogensbeheer B.V.'s portfolio, making the stock its 4th largest position. Mn Services Vermogensbeheer B.V.'s holdings in Eli Lilly and Company were worth $200,926,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in the business. Vanguard Group Inc. increased its position in shares of Eli Lilly and Company by 0.9% in the third quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company's stock worth $37,908,273,000 after acquiring an additional 659,838 shares in the last quarter. Morgan Stanley boosted its stake in shares of Eli Lilly and Company by 0.7% in the third quarter. Morgan Stanley now owns 12,545,572 shares of the company's stock valued at $6,738,605,000 after purchasing an additional 83,915 shares during the period. Northern Trust Corp boosted its stake in shares of Eli Lilly and Company by 3.6% in the third quarter. Northern Trust Corp now owns 10,158,275 shares of the company's stock valued at $5,456,314,000 after purchasing an additional 355,317 shares during the period. Norges Bank purchased a new position in shares of Eli Lilly and Company in the fourth quarter valued at $3,416,206,000. Finally, International Assets Investment Management LLC boosted its stake in shares of Eli Lilly and Company by 61,268.8% in the fourth quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company's stock valued at $42,802,530,000 after purchasing an additional 7,330,815 shares during the period. Institutional investors and hedge funds own 82.53% of the company's stock.

Analyst Upgrades and Downgrades

LLY has been the subject of several analyst reports. Citigroup upped their target price on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the company a "buy" rating in a research note on Tuesday, April 2nd. Wells Fargo & Company upped their target price on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the company an "overweight" rating in a research note on Tuesday, February 6th. Erste Group Bank upgraded shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a research note on Wednesday, April 3rd. Cantor Fitzgerald reiterated an "overweight" rating and set a $815.00 price objective on shares of Eli Lilly and Company in a research note on Monday, April 1st. Finally, The Goldman Sachs Group increased their price objective on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the company a "neutral" rating in a research note on Thursday. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company's stock. According to MarketBeat.com, Eli Lilly and Company currently has a consensus rating of "Moderate Buy" and a consensus target price of $728.05.

Eli Lilly and Company Stock Performance

Shares of LLY stock traded down $7.95 during trading hours on Friday, reaching $751.64. The stock had a trading volume of 2,495,037 shares, compared to its average volume of 2,285,401. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73. Eli Lilly and Company has a twelve month low of $367.35 and a twelve month high of $800.78. The firm has a 50-day simple moving average of $761.77 and a 200-day simple moving average of $653.35. The firm has a market capitalization of $714.18 billion, a PE ratio of 129.59, a price-to-earnings-growth ratio of 1.67 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, topping analysts' consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The business had revenue of $9.35 billion for the quarter, compared to analysts' expectations of $8.95 billion. During the same quarter last year, the company earned $2.09 EPS. The company's revenue for the quarter was up 28.1% compared to the same quarter last year. As a group, equities analysts forecast that Eli Lilly and Company will post 12.45 earnings per share for the current year.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 78,573 shares of the firm's stock in a transaction dated Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the transaction, the insider now owns 99,333,810 shares of the company's stock, valued at approximately $64,375,262,246.70. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In the last 90 days, insiders have sold 133,785 shares of company stock valued at $86,537,034. Company insiders own 0.13% of the company's stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.